Literature DB >> 16769779

Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?

O Flossmann, R B Jones, D R W Jayne, R A Luqmani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16769779      PMCID： PMC1798207          DOI： 10.1136/ard.2005.048900

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  30 in total

1.  A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS).

Authors:  J H Stone; G S Hoffman; P A Merkel; Y I Min; M L Uhlfelder; D B Hellmann; U Specks; N B Allen; J C Davis; R F Spiera; L H Calabrese; F M Wigley; N Maiden; R M Valente; J L Niles; K H Fye; J W McCune; E W St Clair; R A Luqmani
Journal:  Arthritis Rheum       Date:  2001-04

Review 2.  Pathophysiology of ANCA-associated vasculitides: are ANCA really pathogenic?

Authors:  P Heeringa; J W Cohen Tervaert
Journal:  Kidney Int       Date:  2004-05       Impact factor: 10.612

Review 3.  T-cell-B-cell cooperation.

Authors:  N A Mitchison
Journal:  Nat Rev Immunol       Date:  2004-04       Impact factor: 53.106

4.  T cell activation in rheumatoid synovium is B cell dependent.

Authors:  S Takemura; P A Klimiuk; A Braun; J J Goronzy; C M Weyand
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

5.  Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice.

Authors:  Hong Xiao; Peter Heeringa; Peiqi Hu; Zhi Liu; Minglang Zhao; Yasuaki Aratani; Nobuyo Maeda; Ronald J Falk; J Charles Jennette
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

6.  B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.

Authors:  R John Looney; Jennifer H Anolik; Debbie Campbell; Raymond E Felgar; Faith Young; Lois J Arend; James A Sloand; Joseph Rosenblatt; Iñaki Sanz
Journal:  Arthritis Rheum       Date:  2004-08

7.  A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.

Authors:  David Jayne; Niels Rasmussen; Konrad Andrassy; Paul Bacon; Jan Willem Cohen Tervaert; Jolanta Dadoniené; Agneta Ekstrand; Gill Gaskin; Gina Gregorini; Kirsten de Groot; Wolfgang Gross; E Christiaan Hagen; Eduardo Mirapeix; Erna Pettersson; Carl Siegert; Alberto Sinico; Vladimir Tesar; Kerstin Westman; Charles Pusey
Journal:  N Engl J Med       Date:  2003-07-03       Impact factor: 91.245

8.  Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab).

Authors:  K Arzoo; S Sadeghi; H A Liebman
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

Review 9.  Antineutrophil cytoplasmic autoantibodies and pathophysiology: new insights from animal models.

Authors:  Dennis Huugen; Jan Willem Cohen Tervaert; Peter Heeringa
Journal:  Curr Opin Rheumatol       Date:  2004-01       Impact factor: 5.006

10.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Authors:  Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw
Journal:  N Engl J Med       Date:  2004-06-17       Impact factor: 91.245
View more
  6 in total

1.  Can rheumatoid vasculitis predate a diagnosis of rheumatoid arthritis?

Authors:  Sarah Sacks; Alan Steuer
Journal:  Eur J Rheumatol       Date:  2017-03-01

2.  Lymphocyte counts in patients with ANCA-associated vasculitis.

Authors:  Andreas Holbro; Philipp Schuetz; Christoph Berger; Christoph Hess; Thomas Daikeler
Journal:  Rheumatol Int       Date:  2008-11-08       Impact factor: 2.631

Review 3.  [Wegener's granulomatosis and microscopic polyangiitis].

Authors:  K de Groot; E Reinhold-Keller
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

Review 4.  Anti-neutrophil cytoplasmic (ANCA) and anti-glomerular basement membrane (GBM) autoantibodies in necrotizing and crescentic glomerulonephritis.

Authors:  Sofia Lionaki; J Charles Jennette; Ronald J Falk
Journal:  Semin Immunopathol       Date:  2007-10-18       Impact factor: 9.623

Review 5.  Unmet Needs in the Pathogenesis and Treatment of Vasculitides.

Authors:  Francesco Muratore; Giulia Pazzola; Alessandra Soriano; Nicolò Pipitone; Stefania Croci; Martina Bonacini; Luigi Boiardi; Carlo Salvarani
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

Review 6.  An approach to the diagnosis and management of systemic vasculitis.

Authors:  A Miller; M Chan; A Wiik; S A Misbah; R A Luqmani
Journal:  Clin Exp Immunol       Date:  2010-01-12       Impact factor: 4.330
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.